{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:19:46Z","timestamp":1784726386808,"version":"3.55.0"},"reference-count":44,"publisher":"American Association for Cancer Research (AACR)","issue":"13","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072881"],"award-info":[{"award-number":["82072881"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82273205"],"award-info":[{"award-number":["82273205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203665"],"award-info":[{"award-number":["82203665"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Shanghai","award":["20ZR1409000"],"award-info":[{"award-number":["20ZR1409000"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["22Y31900502"],"award-info":[{"award-number":["22Y31900502"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100016983","name":"Shanghai Clinical Research Center","doi-asserted-by":"crossref","award":["22M1940200"],"award-info":[{"award-number":["22M1940200"]}],"id":[{"id":"10.13039\/501100016983","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Aberrant sialylation functions as an important modulator of all steps of malignant transformation. Therefore, targeting sialylation regulators, such as sialyltransferases and neuraminidases, is a potential strategy for treating cancer. Here, we found that elevated \u03b12,3-sialyltransferase III (St3gal3) was associated with dismal prognosis in high-grade serous ovarian carcinoma (HGSC). St3gal3 knockdown antagonized subcutaneous tumor growth in immunocompetent, but not immunodeficient mice, with enhanced accumulation of functional CD8+ T cells and antitumor immune gene signatures. St3gal3 knockdown inhibited intraperitoneal tumor growth and repolarized tumor-associated macrophages from a protumorigenic M2-like to a tumor-suppressive M1-like phenotype. In vitro, St3gal3 knockdown tumor cells guided bone marrow\u2013derived macrophages (BMDM) toward the M1-like phenotype under both direct contact and distant Transwell coculture conditions. Depletion of macrophages rescued the suppressed tumor growth induced by St3gal3 knockdown and completely suppressed infiltration of functional CD8+ T cells that rely on macrophage-derived CXCL10. St3gal3 engendered an immunosuppressive HGSC microenvironment characterized by an abundance of pro-tumorigenic macrophages and reduced cytotoxic T-cell infiltration. In vivo, St3gal3 knockdown improved effectiveness of dual immune checkpoint blockade (ICB) with \u03b1PD-1 and \u03b1CTLA4 antibodies. Preclinical inhibition of sialylation with ambroxol resulted in decreased tumor growth and prolonged the survival of tumor-bearing mice, which was enhanced by the addition of dual ICB. These findings indicate that altered sialylation induced by St3gal3 upregulation promotes a tumor-suppressive microenvironment in HGSC and targeting \u03b12,3-sialylation may reprogram the immunosuppressive tumor microenvironment and improve the efficacy of immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Blocking sialylation augments antitumor immunity and enhances response to immune checkpoint blockade therapy, highlighting a potential therapeutic approach for treating patients with high-grade serous ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-22-3260","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T16:42:15Z","timestamp":1683909735000},"page":"2171-2186","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer"],"prefix":"10.1158","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9242-1440","authenticated-orcid":false,"given":"Kankan","family":"Cao","sequence":"first","affiliation":[{"name":"1Shanghai Key Laboratory of Female Reproductive Endocrine\u2013Related Diseases, Obstetrics, and Gynecology Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9297-1335","authenticated-orcid":false,"given":"Guodong","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Shanghai Key Laboratory of Female Reproductive Endocrine\u2013Related Diseases, Obstetrics, and Gynecology Hospital, Fudan University, Shanghai, China."},{"name":"2Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0601-9090","authenticated-orcid":false,"given":"Moran","family":"Yang","sequence":"additional","affiliation":[{"name":"1Shanghai Key Laboratory of Female Reproductive Endocrine\u2013Related Diseases, Obstetrics, and Gynecology Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-6111","authenticated-orcid":false,"given":"Yiying","family":"Wang","sequence":"additional","affiliation":[{"name":"1Shanghai Key Laboratory of Female Reproductive Endocrine\u2013Related Diseases, Obstetrics, and Gynecology Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2693-5261","authenticated-orcid":false,"given":"Mengdi","family":"He","sequence":"additional","affiliation":[{"name":"1Shanghai Key Laboratory of Female Reproductive Endocrine\u2013Related Diseases, Obstetrics, and Gynecology Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1091-6316","authenticated-orcid":false,"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Shanghai Key Laboratory of Female Reproductive Endocrine\u2013Related Diseases, Obstetrics, and Gynecology Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-7462","authenticated-orcid":false,"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"3Department of Gynecologic Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5646-0298","authenticated-orcid":false,"given":"Jiaqi","family":"Lu","sequence":"additional","affiliation":[{"name":"2Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0200-8981","authenticated-orcid":false,"given":"Haiou","family":"Liu","sequence":"additional","affiliation":[{"name":"1Shanghai Key Laboratory of Female Reproductive Endocrine\u2013Related Diseases, Obstetrics, and Gynecology Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"2025112417551324000_bib1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2025112417551324000_bib2","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T cells targeting the cancer-associated tn-glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"2025112417551324000_bib3","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1158\/0008-5472.CAN-17-3376","article-title":"Sialic acid blockade suppresses tumor growth by enhancing T-cell\u2013mediated tumor immunity","volume":"78","author":"B\u00fcll","year":"2018","journal-title":"Cancer Res"},{"key":"2025112417551324000_bib4","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"2025112417551324000_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2025112417551324000_bib6","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2025112417551324000_bib7","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"2025112417551324000_bib8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025112417551324000_bib9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","year":"2017","journal-title":"Cell"},{"key":"2025112417551324000_bib10","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"2025112417551324000_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/cancers14030645","article-title":"Targeting tumor glycans for cancer therapy: successes, limitations, and perspectives","volume":"14","author":"Berois","year":"2022","journal-title":"Cancers"},{"key":"2025112417551324000_bib12","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"2025112417551324000_bib13","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41589-020-0622-x","article-title":"Targeted glycan degradation potentiates the anticancer immune response in vivo","volume":"16","author":"Gray","year":"2020","journal-title":"Nat Chem Biol"},{"key":"2025112417551324000_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmet.2018.03.017","article-title":"Neuraminidase 1 activates insulin receptor and reverses insulin resistance in obese mice","volume":"12","author":"Fougerat","year":"2018","journal-title":"Molecular metabolism"},{"key":"2025112417551324000_bib15","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","article-title":"Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma","volume":"76","author":"Clark","year":"2016","journal-title":"Cancer Res"},{"key":"2025112417551324000_bib16","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1038\/s41467-020-19976-3","article-title":"Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer","volume":"11","author":"Pan","year":"2020","journal-title":"Nat Commun"},{"key":"2025112417551324000_bib17","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.3390\/ijms21176239","article-title":"Knockdown of \u03b12,3-sialyltransferases impairs pancreatic cancer cell migration, invasion and E-selectin-dependent adhesion","volume":"21","author":"Guerrero","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025112417551324000_bib18","doi-asserted-by":"crossref","first-page":"12534","DOI":"10.1002\/anie.201105065","article-title":"High-throughput screening for inhibitors of sialyl- and fucosyltransferases","volume":"50","author":"Rillahan","year":"2011","journal-title":"Angew Chem Int Ed Engl"},{"key":"2025112417551324000_bib19","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/s41591-020-1073-3","article-title":"Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state","volume":"26","author":"Cerezo-Wallis","year":"2020","journal-title":"Nat Med"},{"key":"2025112417551324000_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2025112417551324000_bib21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell\u2013cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"key":"2025112417551324000_bib22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"2025112417551324000_bib23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/ni1451","article-title":"Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2","volume":"8","author":"Hong","year":"2007","journal-title":"Nat Immunol"},{"key":"2025112417551324000_bib24","doi-asserted-by":"crossref","first-page":"eaao5610","DOI":"10.1126\/science.aao5610","article-title":"Recurrent infection progressively disables host protection against intestinal inflammation","volume":"358","author":"Yang","year":"2017","journal-title":"Science"},{"key":"2025112417551324000_bib25","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-09-2904","article-title":"Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects","volume":"16","author":"Zhang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2025112417551324000_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2326-6066.CIR-21-0407","article-title":"B7-H3 suppresses antitumor immunity via the CCL2\u2013CCR2-M2 macrophage axis and contributes to ovarian cancer progression","volume":"10","author":"Miyamoto","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025112417551324000_bib27","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1016\/j.cell.2021.09.014","article-title":"Atlas of clinically distinct cell states and ecosystems across human solid tumors","volume":"184","author":"Luca","year":"2021","journal-title":"Cell"},{"key":"2025112417551324000_bib28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"2025112417551324000_bib29","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-16-2196","article-title":"Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes","volume":"23","author":"Kommoss","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025112417551324000_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MPA.0b013e31829d9090","article-title":"Cell surface sialic acid modulates extracellular matrix adhesion and migration in pancreatic adenocarcinoma cells","volume":"43","author":"Bassaga\u00f1as","year":"2014","journal-title":"Pancreas"},{"key":"2025112417551324000_bib31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1006\/bbrc.1999.0388","article-title":"Cell surface n-acetylneuraminic acid alpha2,3-galactoside-dependent intercellular adhesion of human colon cancer cells","volume":"256","author":"Dimitroff","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"2025112417551324000_bib32","first-page":"4499","article-title":"St3gal3 confers paclitaxel-mediated chemoresistance in ovarian cancer cells by attenuating caspase-8\/3 signaling","volume":"20","author":"Zhang","year":"2019","journal-title":"Mol Med Rep"},{"key":"2025112417551324000_bib33","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.3892\/or.2016.5180","article-title":"ST3Gal III modulates breast cancer cell adhesion and invasion by altering the expression of invasion-related molecules","volume":"36","author":"Cui","year":"2016","journal-title":"Oncol Rep"},{"key":"2025112417551324000_bib34","doi-asserted-by":"crossref","first-page":"101726","DOI":"10.1016\/j.jbc.2022.101726","article-title":"ST6Gal-I\u2013mediated sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances invasion","volume":"298","author":"Rao","year":"2022","journal-title":"J Biol Chem"},{"key":"2025112417551324000_bib35","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1096\/fj.15-270983","article-title":"Sialylation regulates brain structure and function","volume":"29","author":"Yoo","year":"2015","journal-title":"FASEB J"},{"key":"2025112417551324000_bib36","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1002\/ijc.31891","article-title":"Sialylation of vasorin by ST3Gal1 facilitates TGF-beta1\u2013mediated tumor angiogenesis and progression","volume":"144","author":"Yeo","year":"2019","journal-title":"Int J Cancer"},{"key":"2025112417551324000_bib37","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/ni.3552","article-title":"The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9","volume":"17","author":"Beatson","year":"2016","journal-title":"Nat Immunol"},{"key":"2025112417551324000_bib38","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"2025112417551324000_bib39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcancer.2021.08.011","article-title":"Chemotherapy resistance in epithelial ovarian cancer: mechanisms and emerging treatments","volume":"77","author":"Marchetti","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"2025112417551324000_bib40","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bbrc.2016.11.107","article-title":"Alpha2,3-sialyltransferase III knockdown sensitized ovarian cancer cells to cisplatin-induced apoptosis","volume":"482","author":"Wang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"2025112417551324000_bib41","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025112417551324000_bib42","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025112417551324000_bib43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.immuni.2022.11.014","article-title":"Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic Type I interferon responses in hepatocellular carcinoma","volume":"56","author":"Wu","year":"2023","journal-title":"Immunity"},{"key":"2025112417551324000_bib44","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"Vazquez-Garcia","year":"2022","journal-title":"Nature"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-22-3260\/3330587\/can-22-3260.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-22-3260\/3342331\/can-22-3260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/13\/2171\/3343383\/2171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/13\/2171\/3343383\/2171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:55:22Z","timestamp":1764024922000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/83\/13\/2171\/727429\/Attenuation-of-Sialylation-Augments-Antitumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":44,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,5,12]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-22-3260","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.23569589","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6711188.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23627642","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23569592.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23627642.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23569592","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6711188","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23569589.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23627639.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6711188.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6711188.v3","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23627639","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.27027779","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30700564","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27027782.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27027782","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23569589","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23627639","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23627639.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23569589.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30700561","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23569592.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23627642","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23627642.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27027779.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23569592","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}